- Location
sickle cell disease
"-
Children Can Have Strokes and Be Prepared to Respond to Symptoms
Feb 26, 2014Parents and healthcare professionals must be aware that children can have strokes and be prepared to respond to symptoms, according to research presented at the American Stroke Association's International Stroke Conference 2014. As in ...
-
A Collaboration and License Agreement Focused on The Development of Therapeutics
Jan 10, 2014Biogen Idec (NASDAQ: BIIB) and Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that ...
-
Pfizer Has Secured European Commission Approval to Carry out Updates
Oct 21, 2013Pfizer has secured European Commission approval to carry out updates to the summary of product characteristics (SmPC) for its pneumococcal conjugate vaccine (PCV) Prevenar 13, regarding its use in certain high-risk populations. Now the ...
Tags: Pfizer, Label Update
-
EMA Has Granted an Orphan Drug Status to GlycoMimetics' GMI-1070
Sep 17, 2013The European Medicines Agency (EMA) has granted an orphan drug status to US-based clinical-stage biotechnology company GlycoMimetics' GMI-1070 (rivipansel sodium), designed to treat vaso-occlusive crisis (VOC) in patients with sickle cell ...
-
EMA Has Granted an Orphan Drug Status to US-Based Clinical-Stage Biotechnology Company
Sep 17, 2013The European Medicines Agency (EMA) has granted an orphan drug status to US-based clinical-stage biotechnology company GlycoMimetics’ GMI-1070 (rivipansel sodium), designed to treat vaso-occlusive crisis (VOC) in patients with sickle ...
Tags: Orphan Drug, Cell Drug
-
Sangamo BioSciences Has Received a $6.4m Strategic Partnership Grant From The CIRM
May 27, 2013Sangamo BioSciences has received a $6.4m strategic partnership grant from the California Institute for Regenerative Medicine (CIRM) for the development of ZFP Therapeutic for Beta-thalassemia. The application of its zinc finger nuclease ...
Tags: Sangamo, ZFG Therapeutic
-
Bluebird Bio Has Formed a Broad Collaboration with Celgene
Mar 26, 2013Biotechnology company bluebird bio has formed a broad collaboration with Celgene to develop new disease-altering gene therapies in oncology. The multi-year research and development collaboration aims to apply gene therapy technology to ...
-
Bluebird Bio Has Received $9.3m Strategic Partnership Award
Nov 29, 2012bluebird bio has received $9.3m Strategic Partnership Award from California Institute for Regenerative Medicine (CIRM) to support phase 1/2 studies of LentiGlobin to treat beta-thalassemia. bluebird bio chief medical officer David ...
Tags: bluebird bio, LentiGlobin, CIRM
-
Emmaus Are Committed to Bring a Treatment for This Severely Underserved Patient Population
Jun 18, 2012Emmaus Medical, a subsidiary of Emmaus Life Sciences, has received European orphan medicinal product designation for Levoglutamide (L-glutamine) for the treatment of sickle cell disease. Emmaus is at present conducting a trial, at over 30 ...
Tags: sickle cell disease, clinical trial, product designation
-
EMA Recommended Orphan Drug Designation for Erytech Pharma's Product
Jun 14, 2012The Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has recommended Orphan Drug Designation (ODD) for Erytech Pharma's investigational product Enhoxy. The drug, which is used to treat sickle cell ...
Tags: orphan drug designation, Erytech product, debilitating disease
